NLS Pharmaceutics AG
NASDAQ:NLSP
P/E
Price to Earnings
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
Market Cap | P/E | ||||
---|---|---|---|---|---|
CH |
NLS Pharmaceutics AG
NASDAQ:NLSP
|
6.1m USD | -0.5 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -5 347 888.9 | |
US |
Eli Lilly and Co
NYSE:LLY
|
779.7B USD | 127 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4.1T DKK | 46.3 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | -15 783.5 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
353B USD | 9.2 | ||
US |
Merck & Co Inc
NYSE:MRK
|
318B USD | 137.9 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
189B GBP | 38 | ||
CH |
Roche Holding AG
SIX:ROG
|
184.2B CHF | 16 | ||
CH |
Novartis AG
SIX:NOVN
|
182.3B CHF | 11.5 | ||
US |
Pfizer Inc
NYSE:PFE
|
162.4B USD | -525.6 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.